{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"104","upperLimit":"182","value":"134"},{"groupId":"OG001","lowerLimit":"64","upperLimit":"169","value":"110"},{"groupId":"OG002","lowerLimit":"282","upperLimit":"537","value":"386"},{"groupId":"OG003","lowerLimit":"133","upperLimit":"309","value":"236"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"3"}],"units":"Participants"}],"description":"Persistence of CART cells is tested by qPCR in PBMC.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Patients undergo leukapheresis. Patients then receive cyclophosphamide and fludarabine on days -4 to -2. Beginning to 36-96 days after chemotherapy, patients receive BCMA-specific CAR-expressing T lymphocytes IV over 20-30 minutes on day 0. Patients may receive a second dose of BCMA-specific CAR-expressing T lymphocytes IV with or without additional cytoreductive chemotherapy at the discretion of the principal investigator or their designee (sub-investigator).\n\nArm 1 contains patients treated as dose level 1 (50 x 10\\^6 EGFRt cells) Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143: Given IV Cyclophosphamide: Given IV Fludarabine: Given IV Leukapheresis: Undergo leukapheresis","id":"OG000","title":"Treatment (Chemotherapy, BCMA CAR-T Cells) at Dose Level 1"},{"description":"Patients undergo leukapheresis. Patients then receive cyclophosphamide and fludarabine on days -4 to -2. Beginning to 36-96 days after chemotherapy, patients receive BCMA-specific CAR-expressing T lymphocytes IV over 20-30 minutes on day 0. Patients may receive a second dose of BCMA-specific CAR-expressing T lymphocytes IV with or without additional cytoreductive chemotherapy at the discretion of the principal investigator or their designee (sub-investigator).\n\nArm 2 contains patients treated as dose level 2 (150 x 10\\^6 EGFRt cells) Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143: Given IV Cyclophosphamide: Given IV Fludarabine: Given IV Leukapheresis: Undergo leukapheresis","id":"OG001","title":"Treatment (Chemotherapy, BCMA CAR-T Cells) at Dose Level 2"},{"description":"Patients undergo leukapheresis. Patients then receive cyclophosphamide and fludarabine on days -4 to -2. Beginning to 36-96 days after chemotherapy, patients receive BCMA-specific CAR-expressing T lymphocytes IV over 20-30 minutes on day 0. Patients may receive a second dose of BCMA-specific CAR-expressing T lymphocytes IV with or without additional cytoreductive chemotherapy at the discretion of the principal investigator or their designee (sub-investigator).\n\nArm 3 contains patients treated as dose level 3 (300 x 10\\^6 EGFRt cells) Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143: Given IV Cyclophosphamide: Given IV Fludarabine: Given IV Leukapheresis: Undergo leukapheresis","id":"OG002","title":"Treatment (Chemotherapy, BCMA CAR-T Cells) at Dose Level 3"},{"description":"Patients undergo leukapheresis. Patients then receive cyclophosphamide and fludarabine on days -4 to -2. Beginning to 36-96 days after chemotherapy, patients receive BCMA-specific CAR-expressing T lymphocytes IV over 20-30 minutes on day 0. Patients may receive a second dose of BCMA-specific CAR-expressing T lymphocytes IV with or without additional cytoreductive chemotherapy at the discretion of the principal investigator or their designee (sub-investigator).\n\nArm 4 contains patients treated as dose level 4 (450 x 10\\^6 EGFRt cells) Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143: Given IV Cyclophosphamide: Given IV Fludarabine: Given IV Leukapheresis: Undergo leukapheresis","id":"OG003","title":"Treatment (Chemotherapy, BCMA CAR-T Cells) at Dose Level 4"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Assessed from Baseline up to a maximum of 537 days","title":"Duration of Persistence of Adoptively Transferred BCMA CAR-T Cells","type":"SECONDARY","unitOfMeasure":"Days"}